Colocalization of thrombin, PAI-1, and vitronectin in the atherosclerotic vessel wall: A potential regulatory mechanism of thrombin activity by PAI-1/vitronectin complexes

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 4, 2000, Pages 1143-1149

  Stoop, A Allart ^a,c   Lupu, Florea ^b   Pannekoek, Hans ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; PAI 1; Smooth muscle cells; Thrombin; Vitronectin

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; VITRONECTIN;

ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL WALL; COMPLEX FORMATION; ENDOTHELIUM CELL; ENZYME SUBSTRATE; FIBRINOLYSIS; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; VASCULAR SMOOTH MUSCLE;

EID: 0034074308     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.4.1143     Document Type: Article

References (37)

1. Huber R, Carrell RW. Implications of the three-dimensional structure of α1-antitrypsin for structure and function of serpins. Biochemistry. 1989; 28:8951-8966.
2. Deng G, Royle G, Seiffert D, Loskutoff DJ. The PAI-1/vitronectin interaction: two cats in a bag? Thromb Haemost. 1995;74:66-70.
3. van Meijer M, Pannekoek H. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update. Fibrinolysis. 1995; 9:263-276.
4. Ehrlich HJ, Gebbink RK, Keijer J, Linders M, Preissner KT, Pannekoek H. Alteration of serpin specificity by a protein cofactor: vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. J Biol Chem. 1990;265:13029-13035.
5. Ehrlich HJ, Keijer J, Preissner KT, Gebbink RK, Pannekoek H. Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin. Biochemistry. 1991;30:1021-1028.
6. Shubeita HE, Cottey TL, Franke AE, Gerard RD. Mutational and immunochemical analysis of plasminogen activator inhibitor 1. J Biol Chem. 1990;265:18379-18385.
7. Gebbink RK, Reynolds CH, Tollefsen DM, Mertens K, Pannekoek H. Specific glycosaminoglycans support the inhibition of thrombin by plasminogen activator inhibitor 1. Biochemistry. 1993;32:1675-1680.
8. Naski MC, Lawrence DA, Mosher DF, Podor TJ, Ginsburg D. Kinetics of inactivation of α-thrombin by plasminogen activator inhibitor-1: comparison of the effects of native and urea-treated forms of vitronectin. J Biol Chem. 1993;268:12367-12372.
9. van Meijer M, Smilde A, Tans G, Nesheim ME, Pannekoek H, Horrevoets AJ. The suicide substrate reaction between plasminogen activator inhibitor 1 and thrombin is regulated by the cofactors vitronectin and heparin. Blood. 1997;90:1874-1882.
10. Ehrlich HJ, Gebbink RK, Preissner KT, Keijer J, Esmon NL, Mertens K, Pannekoek H. Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix. J Cell Biol. 1991;115:1773-1781.
11. Padro T, Emeis JJ, Steins M, Schmid KW, Kienast J. Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Thromb Vasc Biol. 1995;15:893-902.
12. Shireman PK, McCarthy WJ, Pearce WH, Patterson BK, Shively VP, Cipollone M, Tamarina N, Verrusio EN, Kwaan HC. Elevated levels of plasminogen activator inhibitor type 1 in atherosclerotic aorta. J Vasc Surg. 1996;23:810-818.
13. Preissner KT, Seiffert D. Role of vitronectin and its receptors in haemostasis and vascular remodeling. Thromb Res. 1998;89:1-21.
14. Smith EB, Crosbie L, Carey S. Prothrombin-related antigens in human aortic intima. Semin Thromb Hemost. 1996;22:347-350.
15. Lupu F, Heim D, Bachmann F, Kruithof EK. Expression of LDL receptor-related protein/α2-macroglobulin receptor in human normal and atherosclerotic arteries. Arterioscler Thromb. 1994;14:1438-1444.
16. Stefansson S, Lawrence DA, Argraves WS. Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2. J Biol Chem. 1996; 271:8215-8220.
17. van Meijer M, Stoop A, Smilde A, Preissner KT, van Zonneveld AJ, Pannekoek H. The composition of complexes between plasminogen activator inhibitor 1, vitronectin and either thrombin or tissue-type plasminogen activator. Thromb Haemost. 1997;77:516-521.
18. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A. 1992;89:6998-7002.
19. Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EK. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb. 1993;13:1090-1100.
20. Chomiki N, Henry M, Alessi MC, Anfosso F, Juhan-Vague I. Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemost. 1994;72:44-53.
21. van Aken BE, Seiffert D, Thinnes T, Loskutoff DJ. Localization of vitronectin in the normal and atherosclerotic human vessel wall. Histochem Cell Biol. 1997;107:313-320.
22. Dufourcq P, Louis H, Moreau C, Daret D, Boisseau MR, Lamaziere JM, Bonnet J. Vitronectin expression and interaction with receptors in smooth muscle cells from human atheromatous plaque. Arterioscler Thromb Vasc Biol. 1998;18:168-176.
23. Nelken NA, Soifer SJ, O'Keefe J, Vu TK, Charo IF, Coughlin SR. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest. 1992;90:1614-1621.
24. McNamara CA, Sarembock IJ, Gimple LW, Fenton JW II, Coughlin SR, Owens GK. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest. 1993;91:94-98.
25. Kranzhofer R, Clinton SK, Ishii K, Coughlin SR, Fenton JW II, Libby P. Thrombin potently stimulates cytokine production in human vascular smooth muscle cells but not in mononuclear phagocytes. Circ Res. 1996; 79:286-294.
26. Rade JJ, Schulick AH, Virmani R, Dichek DA. Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury. Nat Med. 1996;2:293-298.
27. Xu Y, Slayter HS. Immunocytochemical localization of endogenous anti-thrombin III in the vasculature of rat tissues reveals locations of anticoagulantly active heparan sulfate proteoglycans. J Histochem Cytochem. 1994;42:1365-1376.
28. Lijnen HR, Lupu F, Moons L, Carmeliet P, Goulding D, Collen D. Temporal and topographic matrix metalloproteinase expression after vascular injury in mice. Thromb Haemost. 1999;81:799-807.
29. Kettner C, Shaw E. Inactivation of trypsin-like enzymes with peptides of arginine chloromethyl ketone. Methods Enzymol. 1981;80(pt C):826-842.
30. Kruithof EK, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood. 1984;64:907-913.
31. Colman RW, Marder VJ, Salzman EW, Hirsh J. Overview of hemostasis. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, Pa: JB Lippincott Co; 1994:3-18.
32. Taubman MB, Fallon JT, Schecter AD, Giesen P, Mendlowitz M, Fyfe BS, Marmur JD, Nemerson Y. Tissue factor in the pathogenesis of atherosclerosis. Thromb Haemost. 1997;78:200-204.
33. Padro T, Steins M, Li CX, Mesters RM, Hammel D, Scheld HH, Kienast J. Comparative analysis of plasminogen activator inhibitor-1 expression in different types of atherosclerotic lesions in coronary arteries from human heart explants. Cardiovasc Res. 1997;36:28-36.
34. Carmeliet P, Moons L, Lijnen R, Janssens S, Lupu F, Collen D, Gerard RD. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation. 1997;96:3180-3191.
35. Zheng X, Saunders TL, Camper SA, Samuelson LC, Ginsburg D. Vitronectin is not essential for normal mammalian development and fertility. Proc Natl Acad Sci U S A. 1995;92:12426-12430.
36. Sun WY, Witte DP, Degen JL, Colbert MC, Burkart MC, Holmback K, Xiao Q, Bugge TH, Degen SJ. Prothrombin deficiency results in embryonic and neonatal lethality in mice. Proc Natl Acad Sci U S A. 1998;95:7597-7602.
37. Connolly AJ, Ishihara H, Kahn ML, Farese RV Jr, Coughlin SR. Role of the thrombin receptor in development and evidence for a second receptor. Nature. 1996;381:516-519.